24 completed, 4 recruiting, 2 active not recruiting, 2 not yet recruiting. 36 Phase 1, 18 Phase 2.
Follow Obsessive-Compulsive Disorder: new trials by email Literature Review of Obsessive-Compulsive Disorder trials Research Report on Obsessive-Compulsive Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Psilocybin for Treatment of OCD-2 Low Dose Psilocybin, High Dose Psilocybin - Obsessive - Compulsive Disorder | Phase 1 / Phase 2 | Not yet recruiting | Francisco A Moreno | 20 | 2026-09-08 | 2026-05-12 |
| Sonication-based OCD Neurosurgical Intervention Via Capsulotomy ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy - Obsessive-Compulsive Disorder | Phase 1 / Phase 2 | Not yet recruiting | Brigham and Women's Hospital | 66 | 2026-08-01 | 2026-02-25 |
| Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder. Psilocybin 10 mg, Psilocybin 20 mg, Psilocybin 30 mg - Obsessive-Compulsive Disorder | Phase 1 | Recruiting | Francisco A Moreno | 30 | 2026-05-18 | 2026-07-23 |
| Pilot Study of RR-HNK in OCD RR-HNK/Hydroxynorketamine, Placebo - Obsessive-Compulsive Disorder | Phase 1 / Phase 2 | Recruiting | Carolyn Rodriguez | 45 | 2026-01-23 | 2026-08-12 |
| Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for Refractory Anorexia Nervosa With Comorbid Obsessive Compulsive Disorder or Major Depressive Disorder ExAblate Neuro 4000 - Anorexia Nervosa (DSM-IV Revised Criteria) | Phase 1 | Recruiting | Sunnybrook Health Sciences Centre | 10 | 2025-08-01 | 2025-08-14 |
| The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective. Group A. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by anxiety disorders and depression., Group B. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by PTSD, Group C. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder. - Anxiety, Depression | Phase 1 | Completed | Rakitzi, Stavroula | 107 | 2025-06-02 | 2026-08-04 |
| Priming CBT With rTMS for OCD rTMS, CBT - Obsessive Compulsive Disorder (OCD) | Phase 1 | Active not recruiting | Sunnybrook Health Sciences Centre | 10 | 2025-02-05 | 2026-03-04 |
| Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD Psilocybin - Obsessive-Compulsive Disorder | Phase 1 | Completed | Centre for Addiction and Mental Health | 10 | 2024-09-01 | 2026-09-24 |
| Effects of Repeated Psilocybin Dosing in OCD Psilocybin - Obsessive-Compulsive Disorder | Phase 1 | Active not recruiting | Yale University | 28 | 2023-07-20 | 2026-06-04 |
| PsilOCD: A Pharmacological-Challenge Feasibility Study Psilocybin (COMP360) - Obsessive-Compulsive Disorder | Phase 1 | Completed | Imperial College London | 19 | 2022-10-28 | 2024-11-06 |
| A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline Propranolol, Prazosin - Post-traumatic Stress Disorder (PTSD) | Phase 1 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 34 | 2022-09-07 | 2024-01-23 |
| Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder Nabilone, Placebo - Obsessive-Compulsive Disorder | Phase 1 / Phase 2 | Withdrawn | New York State Psychiatric Institute | 2022-03-01 | 2024-05-21 | |
| Self-control and Body-focused Repetitive Behaviors self-control - Trichotillomania (Hair-Pulling Disorder), Skin-Picking | Phase 1 | Completed | American University | 80 | 2020-06-30 | 2022-11-07 |
| Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD Fluoxetine - immediate treatment, Fluoxetine - delayed treatment - Obsessive-Compulsive Disorder | Phase 1 / Phase 2 | Recruiting | Yale University | 100 | 2019-10-14 | 2026-09-22 |
| Rituximab for Obsessive-compulsive Disorder. (RITS-PO-2019) Rituximab - Obsessive-Compulsive Disorder, Treatment Resistant Disorders | Phase 1 | Completed | Region Örebro County | 11 | 2019-08-08 | 2022-05-10 |
| Psilocybin for Treatment of Obsessive Compulsive Disorder Psilocybin 100 mcg/kg, Psilocybin 300 mcg/kg, Lorazepam 1 mg - Obsessive-compulsive Disorder (OCD) | Phase 1 | Completed | University of Arizona | 15 | 2019-01-02 | 2024-08-30 |
| Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study. Psilocybin (0.25mg/kg), Niacin (250mg) - Obsessive-Compulsive Disorder | Phase 1 | Completed | Yale University | 28 | 2018-11-13 | 2026-10-16 |
| Bioequivalence Study of Paroxetine Tablets and Paxil® Under Fasting and Fed Conditions in Chinese Healthy Volunteers Paroxetine Hydrochloride Tablet 20 mg, Paxil® 20 mg - Major Depressive Disorder, Obsessive-Compulsive Disorder | Phase 1 | Completed | Beijing Tongren Hospital | 53 | 2018-03-29 | 2018-12-19 |
| Effects of Marijuana on Symptoms of OCD Cannabis, Placebo - Obsessive-Compulsive Disorder | Phase 1 / Phase 2 | Completed | New York State Psychiatric Institute | 14 | 2017-10-01 | 2020-11-18 |
| The Modular Protocol for Mental Health (MPMH) The Modular Protocol for Mental Health, Treatment-as-usual - Major Depressive Disorder, Generalized Anxiety Disorder | Phase 1 / Phase 2 | Completed | Medical Research Council Cognition and Brain Sciences Unit | 43 | 2017-07-18 | 2020-09-29 |
Showing 20 of 36. Sign in to see all of them.
Depressive Disorder, Major (4) · Generalized Anxiety Disorder (4) · Phobia, Social (4) · Anxiety Disorders (3) · Panic Disorder (3) · Stress Disorders, Post-Traumatic (3) · Trichotillomania (2) · Agoraphobia (1) · Anorexia Nervosa (1) · Anxiety, Separation (1) · Asperger Syndrome (1) · Autistic Disorder (1) · Bipolar Disorder (1) · Compulsive Behavior (1)
Mental Disorders (35) · Anxiety Disorders (33) · Mood Disorders (5) · Depressive Disorder (4) · Phobic Disorders (4) · Behavior (3) · Stress Disorders, Traumatic (3) · Trauma and Stressor Related Disorders (3) · Behavioral Symptoms (2) · Disruptive, Impulse Control, and Conduct Disorders (2) · Nervous System Diseases (2) · Neurobehavioral Manifestations (2) · Neurodevelopmental Disorders (2) · Neurologic Manifestations (2)
Psilocybin (7) · Cognitive Behavioral Therapy (5) · Ketamine (2) · Transcranial Magnetic Stimulation (2) · nabilone (2) · 6-hydroxynorketamine (1) · Adenosine Monophosphate (1) · Amisulpride (1) · Behavior Therapy (1) · Deep Brain Stimulation (1) · Fluoxetine (1) · Implosive Therapy (1) · Lorazepam (1) · Memantine (1) · Mental Health (1)
New York State Psychiatric Institute (5) · University of South Florida (3) · Yale University (3) · Francisco A Moreno (2) · Sunnybrook Health Sciences Centre (2) · American University (1) · Beijing Tongren Hospital (1) · Boston University Charles River Campus (1) · Brigham and Women's Hospital (1) · CNS Onlus (1) · Carolyn Rodriguez (1) · Center for Psychological Consultation (1) · Centre for Addiction and Mental Health (1) · GlaxoSmithKline (1) · Imperial College London (1)
United States (24) · Canada (3) · United Kingdom (3) · Belgium (1) · China (1) · France (1) · Greece (1) · Italy (1) · Sweden (1)
Benjamin Kelmendi, MD (2) · Francisco Moreno, MD (2) · Carolyn Rodriguez, MD, PhD (1) · Christopher Pittenger, MD, PhD (1) · Dr David Erritzoe (1) · Dr Luca Pellegrini (1) · Dr. Polyxeni Georgila, M. D. (1) · Dr. Stavroula Rakitzi, PhD (1) · Eric Storch, Ph.D. (1) · Eric Storch, PhD (1) · Francisco A. Moreno, MD (1) · Gail Steketee (1) · Gwyneth Zai, MD, MSc, PhD (1) · Helen B Simpson, M.D., Ph.D. (1)
PMID 17196053, PMID 19005196, PMID 19142108, PMID 20621362, PMID 20951978, PMID 21456040, PMID 23945445, PMID 25526831, PMID 30082367, PMID 34693989, PMID 37181888, PMID 38264632, PMID 39899368, PMID 41825921
K23MH122777 (1), K23MH125315 (1), K24MH121571 (1), R01MH116038 (1), R21MH068539 (1), R34HD065274 (1), R34MH071570 (1), R34MH095885 (1)